Literature DB >> 29746378

Acute Encephalitis Syndrome in Gorakhpur, Uttar Pradesh, 2016: Clinical and Laboratory Findings.

Mahima Mittal1, Vijay Bondre2, Manoj Murhekar3, Hirawati Deval2, Winsley Rose4, Valsan Philip Verghese4, Mahim Mittal1, Gajanan Patil2, Ramsamy Sabarinathan3, Jeromie Wesley Vivian Thangaraj3, Kaliaperumal Kanagasabai3, John Antony Jude Prakash4, Nivedita Gupta5, Manish M Gupte6, Mohan D Gupte5.   

Abstract

BACKGROUND: Seasonal outbreaks of acute encephalitis syndrome (AES) with high fatality have been occurring in Gorakhpur, Uttar Pradesh, India, for several years. We conducted investigations during the 2016 outbreak to identify the etiology.
METHODS: We included 407 hospitalized AES patients with cerebrospinal fluid pleocytosis (>5 cells/mm) in our study. These patients were clinically examined; their blood and cerebrospinal fluid samples were collected and investigated for scrub typhus (ST), Japanese encephalitis virus (JEV), dengue virus and spotted fever group of Rickettsia by serology and/or polymerase chain reaction.
RESULTS: Of the 407 AES patients, 266 (65.4%), 42 (10.3%) and 29 (7.1%) were diagnosed to have ST, JEV and dengue infection, respectively. Four patients were diagnosed to have spotted fever group of Rickettsia infection. A significantly higher proportion of ST patients with AES had hepatomegaly, splenomegaly and facial edema. The common hematologic and biochemical abnormalities among ST-positive patients include thrombocytopenia, raised liver enzymes and bilirubin levels. The case fatality ratio was significantly higher among ST-negative AES patients (36.2% vs. 15.2%; P < 0.05).
CONCLUSIONS: ST accounted for approximately two third of the AES case-patients. Efforts are required to identify the etiology of AES case-patients who are negative for ST, JEV and dengue fever.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29746378     DOI: 10.1097/INF.0000000000002099

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Genotypic Characterization of Orientia tsutsugamushi Isolated From Acute Encephalitis Syndrome and Acute Febrile Illness Cases in the Gorakhpur Area, Uttar Pradesh, India.

Authors:  Nikita Nanaware; Dipen Desai; Anwesha Banerjee; Kamran Zaman; Mahim Mittal; Mahima Mittal; Smita Kulkarni
Journal:  Front Microbiol       Date:  2022-07-05       Impact factor: 6.064

2.  Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine.

Authors:  Krishna Mohan Vadrevu; Venugopal Potula; Vasant Khalatkar; Niranjana S Mahantshetty; Atish Shah; Raches Ella
Journal:  J Infect Dis       Date:  2020-10-01       Impact factor: 5.226

3.  Systematic review of the scrub typhus treatment landscape: Assessing the feasibility of an individual participant-level data (IPD) platform.

Authors:  Kartika Saraswati; Brittany J Maguire; Alistair R D McLean; Sauman Singh-Phulgenda; Roland C Ngu; Paul N Newton; Nicholas P J Day; Philippe J Guérin
Journal:  PLoS Negl Trop Dis       Date:  2021-10-14

4.  Seroprevalence & seroincidence of Orientia tsutsugamushi infection in Gorakhpur, Uttar Pradesh, India: A community-based serosurvey during lean (April-May) & epidemic (October-November) periods for acute encephalitis syndrome.

Authors:  Suchit Kamble; Arati Mane; Suvarna Sane; Suvarna Sonavale; Pallavi Vidhate; Manish Kumar Singh; Raman Gangakhedkar; Mohan Gupte
Journal:  Indian J Med Res       Date:  2020-04       Impact factor: 2.375

5.  Risk Factors for Acquiring Scrub Typhus among Children in Deoria and Gorakhpur Districts, Uttar Pradesh, India, 2017.

Authors:  Jeromie Wesley Vivian Thangaraj; Ravi Vasanthapuram; Leonard Machado; Govindakarnavar Arunkumar; Samir V Sodha; Kamran Zaman; Tarun Bhatnagar; Shafeeq K Shahul Hameed; Arun Kumar; Jazeel Abdulmajeed; Anoop Velayudhan; Avinash Deoshatwar; Anita S Desai; K Hemanth Kumar; Nivedita Gupta; Kayla Laserson; Manoj Murhekar
Journal:  Emerg Infect Dis       Date:  2018-12       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.